<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018806</url>
  </required_header>
  <id_info>
    <org_study_id>ACT17207</org_study_id>
    <secondary_id>U1111-1261-7565</secondary_id>
    <secondary_id>2021-001704-15</secondary_id>
    <nct_id>NCT05018806</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Proof-of-concept Study Evaluating Efficacy and Safety of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Who Are Inadequate Responders or Intolerant to Topical Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel, treatment, Phase 2, double-blind, 2-arm study in adult participants (aged&#xD;
      at least 18 years) with moderate-to-severe atopic dermatitis (AD) and intolerance or&#xD;
      inadequate response to topical corticosteroids (TCS).&#xD;
&#xD;
      The total study duration per participant is expected to be approximately 21 weeks, including:&#xD;
&#xD;
      Screening: up to 4 weeks On-treatment double-blind period: 16 weeks Post-treatment follow-up:&#xD;
      1 week&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">September 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in Eczema Area and Severity Index (EASI) score</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. A higher score means more severe condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Investigator's Global Assessment (IGA) of 0 or 1 (disease free or almost disease free) compared to placebo</measure>
    <time_frame>At Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving EASI-75</measure>
    <time_frame>At Week 16</time_frame>
    <description>Defined as reduction of EASI score by ≥75% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with reduction of weekly average of daily peak pruritus Numerical Rating Scale (PP-NRS) of ≥4 points</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of effect on pruritus</measure>
    <time_frame>Until Week 16</time_frame>
    <description>Defined as ≥4 points reduction of weekly average of daily PP-NRS from baseline during the 16-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in EASI score</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving EASI-50/90</measure>
    <time_frame>At Week 16</time_frame>
    <description>Defined as reduction of EASI score by ≥50% or ≥90% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent body surface area (BSA) of EASI.</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on weekly average of daily PP-NRS.</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Based on daily participant assessments documented in their electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)</measure>
    <time_frame>Up to Week 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of study investigational medicinal product (IMP) discontinuation and withdrawals due to TEAEs</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Rilzabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rilzabrutinib 400 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilzabrutinib</intervention_name>
    <description>Pharmaceutical form: Tablet Route of administration: Oral</description>
    <arm_group_label>Rilzabrutinib</arm_group_label>
    <other_name>PRN1008/SAR444671</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AD as defined by the American Academy of Dermatology Consensus Criteria.&#xD;
&#xD;
          -  History of AD for at least 12 months prior to baseline as determined by the&#xD;
             Investigator through patient interview.&#xD;
&#xD;
          -  Eczema Area and Severity Index (EASI) score ≥ 12 at screening and ≥ 16 at baseline.&#xD;
&#xD;
          -  IGA score ≥ 3 (on the 0 to 4 IGA scale) at baseline.&#xD;
&#xD;
          -  BSA of AD involvement ≥ 10% at baseline.&#xD;
&#xD;
          -  Documented inadequate response or intolerance to TCS within 6 months prior to baseline&#xD;
             visit&#xD;
&#xD;
          -  Baseline PP-NRS score for maximum itch intensity ≥4.&#xD;
&#xD;
          -  All contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  For optional substudy only: Willingness to have 2 tape strips for comparison of&#xD;
             baseline and treatment response.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin comorbidities that may interfere with study assessments such as psoriasis, tinea&#xD;
             corporis, lupus erythematosus.&#xD;
&#xD;
          -  Conditions that may predispose the patient to excessive bleeding.&#xD;
&#xD;
          -  Any other clinically significant disease, condition or medical history that, in the&#xD;
             opinion of the Investigator, would interfere with participant safety, trial&#xD;
             evaluations, and/or trial procedures.&#xD;
&#xD;
          -  Laboratory abnormalities at the screening visit&#xD;
&#xD;
          -  History of serious infections requiring intravenous therapy with the potential for&#xD;
             recurrence or currently active moderate to severe infection at Screening (Grade 2 or&#xD;
             higher) including active coronavirus disease 2019 (COVID-19).&#xD;
&#xD;
          -  Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1&#xD;
             or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  COVID-19 vaccine within 14 days prior to Study Day 1.&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude adequate rilzabrutinib/placebo absorption.&#xD;
&#xD;
          -  Initiation of prescription moisturizers (with or without additives such as ceramide,&#xD;
             hyaluronic acid, urea, or filaggrin), topical anesthetics or antihistamines during the&#xD;
             screening period.&#xD;
&#xD;
          -  Use of TCS, calcineurin (tacrolimus, and/or pimecrolimus) or topical phosphodiesterase&#xD;
             4 inhibitor within 1 week prior to baseline and as concomitant medication.&#xD;
&#xD;
          -  Use of systemic corticosteroids within 4 weeks prior to baseline and as concomitant&#xD;
             medication.&#xD;
&#xD;
          -  Phototherapy for AD or regular use (more than 2 visits per week) of a tanning&#xD;
             booth/parlor within 4 weeks prior to baseline or likely to be required as concomitant&#xD;
             procedure during the study.&#xD;
&#xD;
          -  Use of mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, dapsone,&#xD;
             intravenous immunoglobulin (IVIG), Kineret (anakinra), Enbrel (etanercept), or any&#xD;
             other immunosuppressant not mentioned in this exclusion criterion within 4 weeks prior&#xD;
             to baseline.&#xD;
&#xD;
          -  Use of infliximab, adalimumab, golimumab, abatacept, tocilizumab, certolizumab,&#xD;
             secukinumab, IFN-γ, JAK inhibitors, dupilumab, and any other biologic or&#xD;
             targeted-synthetic disease modifier drug not mentioned in this exclusion criterion or&#xD;
             in exclusion criterion, as well as plasmapheresis within 12 weeks prior to baseline.&#xD;
&#xD;
          -  Use of anti-CD20 drugs such as rituximab, ofatumumab, other long-acting biologics&#xD;
             within 6 months prior to baseline (or shorter if there is documented B cell&#xD;
             reconstitution for anti-CD20 drugs).&#xD;
&#xD;
          -  Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days&#xD;
             of baseline (it is acceptable to change participant to H2 receptor blocking drugs&#xD;
             prior to baseline).&#xD;
&#xD;
          -  Concomitant use of known strong-to-moderate inhibitors and inducers of cytochrome P450&#xD;
             3A (CYP3A) within 14 days or 5 half-lives (whichever is longer) prior to baseline.&#xD;
&#xD;
          -  Previous use of a BTK inhibitor.&#xD;
&#xD;
          -  Has received any investigational drug (or is currently using an investigational&#xD;
             device) within the 30 days before baseline, or at least 5 times the respective&#xD;
             elimination half-life time (whichever is longer).&#xD;
&#xD;
          -  Active TB or a history of incompletely treated TB, Quantiferon positive patients,&#xD;
             Clinically significant abnormality consistent with prior/active TB infection based&#xD;
             upon chest radiograph with at least posterior-anterior view, Suspected extrapulmonary&#xD;
             TB infection, or patients at high risk of contracting TB.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>Ext. option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

